Dogwood Therapeutics, Inc.
corporate_fare Company Profile
Dogwood Therapeutics, Inc. (NASDAQ:DWTX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 25 items for DWTX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-06, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for DWTX spans 10-Q, 8-K, DEF 14A, PRE 14A.
Recent high-impact activity:
- Dogwood Q3 Loss Narrows to $4.9M; Going Concern Doubt Persists With Cash Through March 2027
- Dogwood Narrows Q3 Loss to $4.9M as Halneuron Phase 2b Readout Lands This Month
- Dogwood Raises $5M From 64% Holder Sealbond at $1.22/Share
- Dogwood Raises $5M in Private Placement With CK Life Sciences
- Dogwood Completes Enrollment in Halneuron Phase 2b Trial, Topline Data Due November
Financial Snapshot
Short Interest & Short Volume
1.65 days to coverFINRA reported short interest of 111,693 shares in DWTX as of the October 30, 2026 settlement, a 79.0% increase from the prior period — about 1.6 days to cover at its recent average daily volume. On November 20, 2026, 40.9% of DWTX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for DWTX, detected from its recent SEC filings.
Resale Registration for Sealbond Shares · No New Capital or Dilution
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →